Detailed Coverage

Strides Pharma Science Announces Record FY26 Financial Performance

Consolidated Revenue: ₹4,858.7 crore
Operational PAT: ₹518.1 crore

Reader Takeaway: Strong revenue growth and profit jump driven by ex-US markets; balanced by deleveraging and dividend payout.

What just happened

Strides Pharma Science has reported its best-ever financial performance for the fiscal year 2026. The company achieved a consolidated revenue of ₹4,858.7 crore, marking a 6.4% increase year-on-year. Operational Profit After Tax (PAT) saw a substantial rise of 50.3%, reaching ₹518.1 crore. EBITDA for the year stood at ₹925.3 crore, with an EBITDA margin of 19.0%. The company also proposed a final dividend of ₹5 per equity share for FY 2025-26.

Why this matters

This record performance signals strong operational execution and a favourable shift in the company's business mix towards more profitable segments. The growth in ex-US markets is a significant positive, indicating successful market penetration and expansion strategies. The improved leverage ratio and proposed dividend offer comfort to investors.

The backstory

Strides Pharma Science has been focused on enhancing its profitability and strengthening its market position across key geographies. The company has been strategically managing its product portfolio and expanding its reach, particularly in emerging markets, while also working on reducing its debt.

What changes now

The company's improved financial health and robust performance in the ex-US segment are expected to drive future growth. The recommended dividend provides a direct return to shareholders. Board changes indicate a continuation of strategic oversight.

Risks to watch

Global macro uncertainties and currency fluctuations can impact international operations. Continued focus on deleveraging and maintaining profitability in a competitive pharmaceutical landscape will be key.

Peer comparison

While specific peer comparisons are not detailed in the filing, Strides' growth in ex-US markets suggests a potential advantage over competitors more heavily reliant on mature markets like the US.

Context metrics (time-bound)

Consolidated revenue grew 6.4% year-on-year to ₹4,858.7 crore for FY26. Operational PAT grew 50.3% to ₹518.1 crore. Net debt to EBITDA improved to 1.6x from 1.9x in the prior year.

What to track next

Investors will be keen to see the sustained growth in the ex-US business and the company's progress on its deleveraging targets. The performance of acquired products in the African market will also be important.